Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | USP7 | Q93009 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777930 | 0.79 | GPR119 (0.45) | — | |
| SCHEMBL1995858 | 0.76 | CYP11B1 (0.44) | ALDH1A1EGLN3TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL1664534 | 0.76 | TBXAS1 (0.48) | USP7TBXAS1 | |
| SCHEMBL6777198 | 0.74 | EGLN3 (0.42) | ALDH1A1EGLN3USP7 | |
| SCHEMBL20702823 | 0.73 | TBXAS1 (0.55) | ALDH1A1EGLN3TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL23253117 | 0.68 | CYP46A1 (0.33) | ALDH1A1 | |
| SCHEMBL7452629 | 0.67 | L3MBTL1 (0.56) | ALDH1A1 | |
| SCHEMBL20702372 | 0.66 | AVPR1A (0.32) | ALDH1A1 | |
| SCHEMBL21840110 | 0.66 | CYP46A1 (0.40) | ALDH1A1 | |
| SCHEMBL3961313 | 0.66 | AVPR1A (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | CLIC1, CBR1, CBR3 | ALDH1A1 410/4885EGLN3 658/4885USP7 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.